Lv1
90 积分 2024-11-06 加入
Evaluation of the stopping angiotensin converting enzyme inhibitor compared to angiotensin receptor blocker (STOP ACEi trial) in advanced and progressive chronic kidney disease
11小时前
已完结
Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study
3个月前
已完结
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial
3个月前
已完结
Febuxostat leads to better cardiovascular outcomes compared to allopurinol in patients with advanced chronic kidney disease: A Population-based Cohort Study
3个月前
已完结
Can we crystallize the role of urate-lowering treatment in chronic kidney disease?
3个月前
已完结
Guidelines for Genetic Testing and Management of Alport Syndrome
4个月前
已完结
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
4个月前
已完结
2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis
4个月前
已完结
Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD
4个月前
已完结
Prognostic Models in Nephrology: Where Do We Stand and Where Do We Go from Here? Mapping Out the Evidence in a Scoping Review
4个月前
已完结
皖公网安备34019202002308
